2021
Brief Report: Are Serious Falls Associated With Subsequent Fragility Fractures Among Veterans Living With HIV?
Womack JA, Murphy TE, Ramsey C, Bathulapalli H, Leo-Summers L, Smith AC, Bates J, Jarad S, Gill TM, Hsieh E, Rodriguez-Barradas MC, Tien PC, Yin MT, Brandt C, Justice AC. Brief Report: Are Serious Falls Associated With Subsequent Fragility Fractures Among Veterans Living With HIV? JAIDS Journal Of Acquired Immune Deficiency Syndromes 2021, 88: 192-196. PMID: 34506360, PMCID: PMC8513792, DOI: 10.1097/qai.0000000000002752.Peer-Reviewed Original ResearchMeSH KeywordsAccidental FallsAgedAntiretroviral Therapy, Highly ActiveCohort StudiesFemaleFractures, BoneHIV InfectionsHumansMaleMiddle AgedOsteoporotic FracturesRisk FactorsUnited StatesVeteransConceptsSubsequent fragility fracturesFragility fracturesAntiretroviral therapySerious fallsRisk factorsVeterans Aging Cohort StudyAging Cohort StudyMultivariable logistic regressionUpper arm fracturesMiddle-aged populationYears of ageAlcohol use disorderCohort studyHip fractureVertebral fracturesArm fracturesInjury codesICD9 codesGeneral populationUse disordersLogistic regressionIntegrase inhibitorsOlder adultsRadiology reportsHIV
2020
CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018
Lee J, Humes E, Hogan B, Buchacz K, Eron J, Gill M, Sterling T, Rebeiro P, Lima V, Mayor A, Silverberg M, Horberg M, Moore R, Althoff K, Benson C, Bosch R, Emory-Grady G, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Yip B, Zhu J, Salters K, Gabler K, Buchacz K, Li J, Gebo K, Johns R, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Thorne J, Brown T, Tien P, D’Souza G, Crouzat F, Loutfy M, Smith G, Gupta M, Klein M, Rabkin C, Kroch A, Burchell A, Betts A, Lindsay J, Nijhawan A, Hunter-Mellado R, Mayor A, Gill M, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Bamford L, Karris M, Eron J, Napravnik S, Kitahata M, Crane H, Sterling T, Haas D, Rebeiro P, Turner M, Park L, Justice A, Moore R, Althoff K, Gange S, Kitahata M, Lee J, Saag M, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Althoff K, Freeman A, Kitahata M, Van Rompaey S, Crane H, Morton L, McReynolds J, Lober W, Gange S, Lee J, Hogan B, You B, Humes E, Gerace L, Stewart C, Coburn S. CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. Clinical Infectious Diseases 2020, 73: e2334-e2337. PMID: 33383586, PMCID: PMC8492212, DOI: 10.1093/cid/ciaa1904.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountHIVHIV InfectionsHumansPrescriptionsUnited States
2017
Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older
Lodi S, Costagliola D, Sabin C, del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 76: 311-318. PMID: 28746165, PMCID: PMC5704899, DOI: 10.1097/qai.0000000000001498.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountDrug Administration ScheduleFemaleHIV InfectionsHumansMaleMiddle AgedRegression AnalysisUnited StatesViral LoadConceptsGeneral HIV populationImmediate initiationHIV populationCD4 countCells/US veteransAIDS mortalityAIDS-free individualsNon-AIDS mortalityUS Veteran cohortHIV-positive individualsHIV-CAUSAL CollaborationAntiretroviral therapyCause mortalityAntiretroviral treatmentMedian ageClinical guidelinesVeteran cohortHigh mortalityMortalityCD4Younger participantsRiskBaselineVeteransAssociation of Cannabis, Stimulant, and Alcohol use with Mortality Prognosis Among HIV-Infected Men
Adams JW, Bryant KJ, Edelman J, Fiellin DA, Gaither JR, Gordon AJ, Gordon KS, Kraemer KL, Mimiaga MJ, Operario D, Tate JP, van den Berg JJ, Justice AC, Marshall BDL. Association of Cannabis, Stimulant, and Alcohol use with Mortality Prognosis Among HIV-Infected Men. AIDS And Behavior 2017, 22: 1341-1351. PMID: 28887669, PMCID: PMC5881942, DOI: 10.1007/s10461-017-1905-4.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyLow-risk alcohol useRisk alcohol useMortality riskAlcohol useStimulant useAdjusted longitudinal analysesAging Cohort StudyUnhealthy alcohol useAssociation of cannabisVACS IndexCause mortalityCohort studyPatient populationPrognostic indicatorMortality prognosisHIVStudy periodSubstance useCannabisRiskLongitudinal analysisMenMortalityStimulantsIncreased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population
Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, Burkholder GA, Mathews WC, Silverberg MJ, Sterling TR, Heckbert SR, Budoff MJ, Van Rompaey S, Delaney JAC, Wong C, Tong W, Palella FJ, Elion RA, Martin JN, Brooks JT, Jacobson LP, Eron JJ, Justice AC, Freiberg MS, Klein DB, Post WS, Saag MS, Moore RD, Crane HM. Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 568-576. PMID: 28520615, PMCID: PMC5522001, DOI: 10.1097/qai.0000000000001450.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountComorbidityFemaleHIV InfectionsHumansIncidenceMaleMiddle AgedMyocardial InfarctionNorth AmericaProportional Hazards ModelsRisk AssessmentRisk FactorsViral LoadConceptsTraditional CVD risk factorsDetectable HIV RNACVD risk factorsIncidence rateRisk factorsCD4 countHIV RNAMyocardial infarctionCardiovascular diseaseNorth American AIDS Cohort CollaborationType 1 myocardial infarctionHIV-specific factorsLow CD4 countSuppressive antiretroviral treatmentIncidence rate ratiosCohort CollaborationIncident MINA-ACCORDAggressive managementAntiretroviral treatmentMultivariable analysisAtherosclerosis RiskMI riskCommunity cohortGeneral populationSurvival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Collaboration T, Trickey A, May M, Vehreschild J, Obel N, Gill M, Crane H, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, van Sighem A, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice A, Sterling T, Ingle S, Sterne J. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet HIV 2017, 4: e349-e356. PMID: 28501495, PMCID: PMC5555438, DOI: 10.1016/s2352-3018(17)30066-8.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesFemaleHIV InfectionsHIV-1HumansLife ExpectancyMaleRisk FactorsSurvival AnalysisTime FactorsViral LoadYoung AdultConceptsInitiation of ARTAntiretroviral therapyART initiationCause mortalityHazard ratioLife expectancyCalendar periodCause-specific mortality hazard ratiosYears of ARTFirst yearHIV-1 cohortToxic antiretroviral drugsCombination antiretroviral therapyHIV-positive patientsCD4 cell countManagement of comorbiditiesMortality hazard ratioUK Medical Research CouncilHealth care plannersMedical Research CouncilEDCTP2 programmeCohort studyViral loadAntiretroviral drugsYear survival
2016
First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension Among North American HIV-Infected Adults, 2000–2013
Wong C, Gange SJ, Buchacz K, Moore RD, Justice AC, Horberg MA, Gill MJ, Koethe JR, Rebeiro PF, Silverberg MJ, Palella FJ, Patel P, Kitahata MM, Crane HM, Abraham AG, Samji H, Napravnik S, Ahmed T, Thorne JE, Bosch RJ, Mayor AM, Althoff KN, Research and Design F. First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension Among North American HIV-Infected Adults, 2000–2013. Clinical Infectious Diseases 2016, 64: 459-467. PMID: 28172581, PMCID: PMC5850614, DOI: 10.1093/cid/ciw804.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseHuman immunodeficiency virusDiabetes mellitusAntiretroviral therapyCumulative incidenceKidney diseaseNoncommunicable diseasesNorth American AIDS Cohort CollaborationOccurrence of DMType 2 diabetes mellitusRisk of deathDemographic subgroupsNon-black womenCohort CollaborationHIV populationImmunodeficiency virusTreatment optionsHypertensionAge 70Poisson regressionRacial disparitiesDiseaseBlack womenIncidenceCare
2015
Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada
Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, Buchacz K, Napravnik S, Mayor AM, Horberg MA, Blashill AJ, Willig A, Wester CW, Silverberg MJ, Gill J, Thorne JE, Klein M, Eron JJ, Kitahata MM, Sterling TR, Moore RD. Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Research And Human Retroviruses 2015, 32: 50-58. PMID: 26352511, PMCID: PMC4692122, DOI: 10.1089/aid.2015.0147.Peer-Reviewed Original ResearchConceptsYears of ARTBody mass indexAntiretroviral therapyART initiationMedian body mass indexNormal body mass indexHigher body mass indexWeight gainWhite womenUnited States National HealthART-exposed HIVHIV-1 RNAProportion of overweightMultivariable linear regressionCohort CollaborationNA-ACCORDNon-white womenCohort studyMedian ageObese adultsMass indexObesity prevalenceNational HealthHigh prevalenceHealth complicationsAdherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy
Viswanathan S, Justice AC, Alexander GC, Brown TT, Gandhi NR, McNicholl IR, Rimland D, Rodriguez-Barradas MC, Jacobson LP. Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 493-498. PMID: 25886923, PMCID: PMC4482798, DOI: 10.1097/qai.0000000000000643.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveFemaleHIV InfectionsHumansMaleMedication AdherenceMiddle AgedRNA, ViralSensitivity and SpecificityConceptsHIV RNA suppressionOdds of suppressionActive antiretroviral therapyRNA suppressionHAART regimenAntiretroviral therapyVeterans Aging Cohort Study Virtual CohortHighly Active Antiretroviral TherapyFirst HAART regimenProtease inhibitor usersRepeated-measures logistic regressionVeterans' Affairs pharmacyViral load suppressionHAART usersNew HAARTRegimen typeInhibitor usersHIV infectionNonnucleoside reverseLow adherenceAdherence levelsPerfect adherenceVirtual cohortLogistic regressionDuration of timeComparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study
Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA, Collaboration H. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. The Lancet HIV 2015, 2: e335-e343. PMID: 26423376, PMCID: PMC4643831, DOI: 10.1016/s2352-3018(15)00108-3.Peer-Reviewed Original ResearchConceptsNeed of ARTHIV RNA viral loadCD4 countAntiretroviral therapyHIV-positive individualsMean survival timeImmediate initiationHIV diagnosisCohort studyViral loadRelative riskHigh-income countriesProportion of individualsSurvival timeInitiation of ARTART initiation strategiesImmediate antiretroviral therapyLow CD4 countMedian CD4 countObservational cohort studyAIDS-free survivalHIV-1 infectionDiagnosis of HIVViral load measurementsHIV-CAUSAL CollaborationSmoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America
Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, Costagliola D, d’Arminio A, Cavassini M, Smith C, Justice AC, Gill J, Sterne JA, Obel N. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS 2015, 29: 221-229. PMID: 25426809, PMCID: PMC4284008, DOI: 10.1097/qad.0000000000000540.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesEuropeFemaleHIV InfectionsHumansLife ExpectancyMaleMiddle AgedNorth AmericaSmokingConceptsMortality rate ratiosCardiovascular diseaseLife expectancyBackground populationNon-AIDS malignanciesAntiretroviral therapy initiationProportion of smokersNorth American cohortSmoking-related mortalityCause of deathMore life yearsAIDS malignanciesAntiretroviral therapyPrevious smokersTherapy initiationSmoking cessationSmoking increasesExcess mortalityAge 35HIVSmokersAmerican cohortSmokingLife yearsHigh mortalityBoosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries
Cain L, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins J, Sterne J, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende M, Abgrall S, Costagliola D, Hernán M. Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases 2015, 60: 1262-1268. PMID: 25567330, PMCID: PMC4447777, DOI: 10.1093/cid/ciu1167.Peer-Reviewed Original ResearchConceptsAtazanavir regimenVirologic failureProspective studyNucleoside reverse transcriptase inhibitor (NRTI) backboneFirst-line antiretroviral regimensReverse transcriptase inhibitor backboneAIDS-free individualsTreat hazard ratiosCD4 cell countCurrent clinical guidelinesHuman immunodeficiency virusRandomized clinical trialsAdjusted intentionAntiretroviral regimensAtazanavir groupBoosted atazanavirContaining RegimensVirologic outcomesCD4 countNRTI backboneHazard ratioClinical outcomesImmunodeficiency virusClinical guidelinesClinical trialsSex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US
Jarrin I, Moreno S, Ingle S, May M, Sterling T, Justice A, Bickel M, Crane H, Mugavero M, De Wolf F, Jung N, Cescon A, Garcia I, Elzi L, Arminio A, Krause M, Smith C, Guest J, Hessamfar M, Gill J, Sterne J, del Amo J. Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US. Antiviral Therapy 2015, 20: 21-28. PMID: 24675571, DOI: 10.3851/imp2768.Peer-Reviewed Original ResearchConceptsNon-AIDS mortalityInjection drug useAll-causeAntiretroviral therapyAIDS-mortality rateNon-AIDS-related mortalityCause-specific mortalityCD4(+) T-cell countsNon-AIDS infectionsRates of all-causeNon-AIDS malignanciesART Cohort CollaborationT-cell countsHIV-infected adultsHIV-positive patientsHIV-1 RNAAll-cause mortalityCox proportional hazards modelsCohort of individualsHIV-positive menProportional hazards modelART-CCSex differencesCART initiationCause-specific
2014
Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies
Boulle A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, Keiser O, Lampe FC, Giddy J, Ndirangu J, Garone D, Fox M, Ingle SM, Reiss P, Dabis F, Costagliola D, Castagna A, Ehren K, Campbell C, Gill MJ, Saag M, Justice AC, Guest J, Crane HM, Egger M, Sterne JA. Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. PLOS Medicine 2014, 11: e1001718. PMID: 25203931, PMCID: PMC4159124, DOI: 10.1371/journal.pmed.1001718.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCohort StudiesCooperative BehaviorEuropeFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansMaleMiddle AgedMortalityNorth AmericaProspective StudiesSouth AfricaConceptsAntiretroviral therapyHigh early mortalityEarly mortalityMortality rateAdjusted mortality rate ratioCumulative mortalityDeath registry linkageHIV-1 infectionMortality rate ratiosNorth American cohortSouth African cohortAdvanced diseaseCD4 countRegistry linkageProspective studyVital statusHIV treatmentEuropean cohortPoor ascertainmentHIV-1African cohortAmerican cohortPatientsMortalityCohortAntiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions
Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán MA. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 2014, 83: 134-141. PMID: 24907236, PMCID: PMC4117168, DOI: 10.1212/wnl.0000000000000564.Peer-Reviewed Original ResearchConceptsHigher CPE scoreLower CPE scoreAntiretroviral therapy regimenProgressive multifocal leukoencephalopathyCPE scoreHIV dementiaHazard ratioCryptococcal meningitisMultifocal leukoencephalopathyTherapy regimenAntiretroviral therapy-naive individualsCNS penetration-effectiveness (CPE) scoreTherapy-naive individualsRespective hazard ratiosCases of toxoplasmosisHIV-CAUSAL CollaborationIncidence of AIDSAntiretroviral penetrationAntiretroviral regimenBaseline regimensInitial regimenNeurologic conditionsNeurologic disordersCNS penetrationRegimenAdjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy
Miller CJ, Baker JV, Bormann AM, Erlandson KM, Huppler Hullsiek K, Justice AC, Neuhaus J, Paredes R, Petoumenos K, Wentworth D, Winston A, Wolfson J, Neaton JD, . Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy. PLOS ONE 2014, 9: e95061. PMID: 24728071, PMCID: PMC3984283, DOI: 10.1371/journal.pone.0095061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAntiretroviral Therapy, Highly ActiveCause of DeathFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedMorbidityMortalityRisk FactorsTreatment OutcomeYoung AdultConceptsSerious non-AIDS eventsNon-AIDS eventsComposite outcomeAntiretroviral therapyCardiovascular diseaseSuppressive combination antiretroviral therapyEnd-stage renal diseaseEndpoint review committeeFive-year KaplanNon-AIDS cancerCombination antiretroviral therapyHIV RNA levelsSerious adverse eventsSuppressive antiretroviral therapyCause of morbidityLarge international trialCause of deathStudies of interventionsPre-specified criteriaCause mortalityAdverse eventsAIDS eventsEffect of ageMeier estimatesBaseline factorsThe VACS Index Predicts Mortality in a Young, Healthy HIV Population Starting Highly Active Antiretroviral Therapy
Bebu I, Tate J, Rimland D, Mesner O, Macalino GE, Ganesan A, Okulicz JF, Bavaro M, Weintrob AC, Justice AC, Agan BK. The VACS Index Predicts Mortality in a Young, Healthy HIV Population Starting Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 65: 226-230. PMID: 24226058, PMCID: PMC4091811, DOI: 10.1097/qai.0000000000000045.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgingAntiretroviral Therapy, Highly ActiveCohort StudiesDecision Support TechniquesFemaleHIV InfectionsHumansMaleProspective StudiesRisk AssessmentSurvival AnalysisUnited StatesConceptsVACS IndexActive antiretroviral therapyCause mortalityAntiretroviral therapyHIV populationVeterans Aging Cohort Study (VACS) IndexActive antiretroviral therapy (HAART) initiationAntiretroviral therapy initiationPrediction of mortalityGood discriminationNHS subjectsTherapy initiationDifferent time pointsStudy cohortSimilar patientsClinical variablesEarly risk assessmentMedical historyVAC indexHealthy populationMortalityStudy indicesOutcome predictionTime pointsLaboratory data
2013
Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans
Anderson JP, Tchetgen E, Re V, Tate JP, Williams PL, Seage GR, Horsburgh CR, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Klein MB, Justice AC. Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans. Clinical Infectious Diseases 2013, 58: 719-727. PMID: 24285848, PMCID: PMC3922212, DOI: 10.1093/cid/cit779.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntiretroviral Therapy, Highly ActiveCohort StudiesCoinfectionHepatitis CHIV InfectionsHumansLiver FailureMaleMiddle AgedVeteransYoung AdultConceptsHepatitis C virusInitiation of ARTAntiretroviral therapyHepatic decompensationHazard ratioVeterans Aging Cohort Study Virtual CohortHIV/HCV-coinfected patientsHuman immunodeficiency virus (HIV) coinfectionEnd-stage liver diseaseHepatic decompensation eventsIncident hepatic decompensationLiver disease outcomesCombination antiretroviral therapyImmunodeficiency virus coinfectionHospital discharge diagnosisSpontaneous bacterial peritonitisCopies/mLMarginal structural modelsART initiationART regimenDecompensation eventsHIV RNAVariceal hemorrhageBacterial peritonitisLiver failureThe Next Therapeutic Challenge in HIV: Polypharmacy
Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. The Next Therapeutic Challenge in HIV: Polypharmacy. Drugs & Aging 2013, 30: 613-628. PMID: 23740523, PMCID: PMC3715685, DOI: 10.1007/s40266-013-0093-9.BooksMeSH KeywordsAgingAntiretroviral Therapy, Highly ActiveComorbidityDecision Support Systems, ClinicalHIV InfectionsHumansMedication ReconciliationPolypharmacyPrecision MedicineConceptsAntiretroviral therapyHIV infectionSerious adverse drug eventsChronic antiretroviral therapyHarms of polypharmacyLifelong antiretroviral therapyRisk of polypharmacyCombination antiretroviral therapyNumber of medicationsAdverse drug eventsOrgan system injuryDecades of lifePhysiologic frailtyHIV patientsMore medicationsComorbid diseasesGeriatric syndromesImmune dysfunctionMedication adherenceMost HIVTherapeutic challengeChronic inflammationSystem injuryDrug eventsPolypharmacyCohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)
May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne J, Collaboration T. Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal Of Epidemiology 2013, 43: 691-702. PMID: 23599235, PMCID: PMC4052127, DOI: 10.1093/ije/dyt010.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAge FactorsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBiomarkersCD4 Lymphocyte CountCohort StudiesCoinfectionEuropeFemaleHIV InfectionsHumansLife ExpectancyNorth AmericaPregnancyPrognosisResidence CharacteristicsRisk FactorsSex FactorsSocioeconomic FactorsTime FactorsViral LoadConceptsAntiretroviral Therapy Cohort CollaborationCombination antiretroviral therapyAntiretroviral therapyCohort CollaborationHIV biomarkersCohort studyClinical eventsHuman immunodeficiency virus-infected individualsEffective combination antiretroviral therapyIndividual cohort studiesVirus-infected individualsHIV Cohort StudyHIV-1 infectionImmune deficiency syndromeCause of deathART regimenHepatitis CAdult patientsAIDS eventsPatient demographicsRisk factorsDeficiency syndromeLiver enzymesPrognostic analysisDrug use